UNSPSC 51263112: Bucindolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9UO06K7CE, chemically known as 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile but generally known as bucindolol, which bears US NIH Compound Identifier 51045. Bucindolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bucindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05945MIG.

UNSPSC 51263112 Bucindolol is a Commodity code that captures state and local procurement of specific pharmaceutical products and related medical supplies. Recent state and local solicitations under this code show purchases of naloxone and drug deactivation systems alongside pharmacy benefit management and direct-to-manufacturer prescription programs. State and local government buyers include county health departments, state health and human services agencies, and community health systems pursuing both emergency response capabilities and pharmaceutical supply chain optimization. The work ranges from straightforward supply purchases with quarterly delivery schedules to complex pharmacy benefit initiative planning that explores direct relationships between public agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.

Seminole County, Florida issued an IFB in June 2026 (IFB60459723LAS, response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with all shipping and delivery costs included in bids. The Texas Health and Human Services Commission issued an RFI in April 2026 (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to enable direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers without intermediaries. Recent activity concentrates in Florida and Texas, with solicitations addressing both immediate supply needs and longer-term pharmaceutical supply chain restructuring at the state level.